<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137893">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942681</url>
  </required_header>
  <id_info>
    <org_study_id>TRIGU1309</org_study_id>
    <secondary_id>UMIN000011491</secondary_id>
    <nct_id>NCT01942681</nct_id>
  </id_info>
  <brief_title>Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride</brief_title>
  <acronym>FRESH</acronym>
  <official_title>Multi-institution Study on Efficacy and Safety of Propiverine Hydrochloride for Female Patients With Urge and Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Informatics Center, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shinshu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Informatics Center, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy and safety that the occurrence of incontinence is
      significantly decrease using the propiverine hydrochloride for 200 female patients with
      mixed (stress and urge) urinary incontinence in one week during a twelve-week treatment
      period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurrence of incontinence</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in occurrence of incontinence during a twelve-week treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of protective pad used</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the number of protective pad used during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction ratio of the occurrence for incontinence</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in reduction ratio of the occurrence for incontinence during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICIQ-Short Form(SF) scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in ICIQ-SF scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>I-QOL scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in I-QOL scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS-QOL scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in IPSS-QOL scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS symptom scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in IPSS symptom scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OABSS symptom scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in OABSS symptom scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in blood pressure during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in pulse rate during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The occurrence of adverse events during a twelve-week treatment period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum urethral closure pressure</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in maximum urethral closure pressure during a twelve-week treatment period</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional profile length</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in functional profile length during a twelve-week treatment period</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Propiverine Hydrochloride Administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Administration of Propiverine Hydrochloride for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine Hydrochloride</intervention_name>
    <description>Administrate Propiverine Hydrochloride for 12 weeks</description>
    <arm_group_label>Propiverine Hydrochloride Administration</arm_group_label>
    <other_name>Bup-4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients with mixed urinary incontinence (MUI)

          2. Patients having symptoms of urinary incontinence for at least 3 months

          3. Patients having at least one episode of urge urinary incontinence per week and 4
             episodes of stress urinary incontinence per week in a bladder diary.

          4. 20 years old or older

          5. Patients who meet all the following criteria in ICIQ-SF (1) &quot;2-3 times or more in one
             week&quot; was selected at Q1. (2) &quot;Small or more&quot; was selected at Q2. (3) &quot;leak at the
             time of cough or sneeze&quot; or &quot;leak at the time of exercise&quot; was selected at Q4.

          6. Less than 100mL of residual urine volume

          7. Written informed consent.

        Exclusion Criteria:

          1. Patients with organ disease such as bladder stones, bladder tumors and urethral
             stricture in the lower urinary tract

          2. Patients with bacterial infections (i.e. bacterial cystitis) or nonbacterial
             infections (i.e. interstitial cystitis)

          3. Patients with advanced lower urinary tract obstruction or urinary retention

          4. Patients without urinary sensation

          5. Patients with overflow incontinence

          6. Patients with history or complications of pelvic organ prolapse

          7. Patients with pyloric, duodenal or intestinal obstruction

          8. Patients with gastric or intestinal atony

          9. Patients with angle-closure glaucoma

         10. Patients with myasthenia gravis

         11. Patients with severe heart disease

         12. Patients with severe constipation

         13. Patients with dementia who are not able to complete the questionnaires

         14. Patients with history of allergic reaction to Propiverine Hydrochloride or other
             similar medicine

         15. Patients with history of surgery that affect urination such as Trans-Obturator
             Tape（TOT）or Tension-free Vaginal Tape（TVT）

         16. Women who are pregnant, lactating, potentially pregnant or willing to get pregnant

         17. Patients with previous surgery of the abdomen and pelvis or radiation within 6 months

         18. Patients who started pelvic floor muscle exercise within 3 months

         19. Patients who took Propiverine Hydrochloride or other similar medicine within 2 weeks
             before entry

         20. Judged as being unsuitable for the trial by physician.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Nishizawa, M.D., Pｈ.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shinshu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomonori Minagawa, M.D., Pｈ.D.</last_name>
    <phone>81-263-37-2661</phone>
    <email>minagawat@shinshu-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Koichi Yamashiro</last_name>
    <phone>81-78-304-6804</phone>
    <email>FRESH@tri-kobe.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomonori Minagawa, M.D., Pｈ.D.</last_name>
      <phone>81-263-37-2661</phone>
      <email>minagawat@shinshu-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Osamu Nishizawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>August 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>female</keyword>
  <keyword>mixed urinary incontinence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
